These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 1803283)

  • 1. [Platelet antiaggregants in the treatment of arterial thrombosis].
    Ferlito S
    Minerva Cardioangiol; 1991 Oct; 39(10):375-89. PubMed ID: 1803283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antithrombotic effects of drugs which suppress platelet function: their potential in prevention growth of tumour cells.
    Turpie AG
    Prog Clin Biol Res; 1982; 89():31-62. PubMed ID: 7051035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Main antithrombotic drugs in the therapy and prevention of arterial and venous thrombosis].
    Ferlito S
    Minerva Cardioangiol; 1996 Jun; 44(6):299-312. PubMed ID: 8927260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Low-dose aspirin in the long-term treatment of the patient with ischemic heart disease].
    Magnani B; Semprini F
    Cardiologia; 1994 Dec; 39(12 Suppl 1):15-21. PubMed ID: 7634259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of antithrombotic drugs in artery disease.
    Gallus AS
    Clin Haematol; 1986 May; 15(2):509-59. PubMed ID: 3524934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiplatelet drugs in cardiovascular prevention: coronary events: acute phase and secondary prevention.
    Prescrire Int; 2000 Jun; 9(47):83-5. PubMed ID: 11010749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiplatelet therapy and progression of coronary artery disease: a placebo-controlled trial with angiographic and clinical follow-up after myocardial infarction.
    Dieker HJ; French JK; Joziasse IC; Brouwer MA; Elliott J; West TM; Webber BJ; Verheugt FW; White HD
    Am Heart J; 2007 Jan; 153(1):66.e1-8. PubMed ID: 17174639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A perspective on platelet-suppressant drug treatment in coronary artery and cerebrovascular disease.
    Genton E
    Circulation; 1980 Dec; 62(6 Pt 2):V111-21. PubMed ID: 6108166
    [No Abstract]   [Full Text] [Related]  

  • 9. Antiplatelet therapy in the prevention of ischaemic stroke.
    Verry M; Panak E; Cazenave JP
    Nouv Rev Fr Hematol (1978); 1994 Jun; 36(3):213-28. PubMed ID: 7971242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Therapeutic measures following acute myocardial infarct: differential use of PTCA, surgery and drugs].
    Noll G; Kaufmann U; Wenzel RR; Lüscher TF
    Schweiz Med Wochenschr; 1996 Feb; 126(5):164-76. PubMed ID: 8685687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aspirin and other platelet-aggregation inhibiting drugs.
    Gallus AS
    Med J Aust; 1985 Jan; 142(1):41-7. PubMed ID: 3880861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiplatelet drugs or dicoumarol: what is the most effective prophylaxis in occlusive arterial disease?
    Poliwoda H; Avenarius HJ
    Int Angiol; 1986; 5(3):169-80. PubMed ID: 2435823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of coronary artery stents on mortality and nonfatal myocardial infarction: meta-analysis of randomized trials comparing a strategy of routine stenting with that of balloon angioplasty.
    Al Suwaidi J; Holmes DR; Salam AM; Lennon R; Berger PB
    Am Heart J; 2004 May; 147(5):815-22. PubMed ID: 15131536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug-eluting coronary stents: many meta-analyses, little benefit.
    Prescrire Int; 2009 Apr; 18(100):70-4. PubMed ID: 19585727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Platelet antiaggregants in the treatment of vasculopathies].
    Honorato J; Montes-Jovellar B
    Angiologia; 1990; 42(1):1-10. PubMed ID: 2181892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38).
    Wiviott SD; Antman EM; Gibson CM; Montalescot G; Riesmeyer J; Weerakkody G; Winters KJ; Warmke JW; McCabe CH; Braunwald E;
    Am Heart J; 2006 Oct; 152(4):627-35. PubMed ID: 16996826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rationale, design and organization of the Second Chinese Cardiac Study (CCS-2): a randomized trial of clopidogrel plus aspirin, and of metoprolol, among patients with suspected acute myocardial infarction. Second Chinese Cardiac Study (CCS-2) Collaborative Group.
    Second Chinese Cardiac Study (CCS-2) Collaborative Group
    J Cardiovasc Risk; 2000 Dec; 7(6):435-41. PubMed ID: 11189013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Antiplatelet therapy in cardiac diseases].
    Aosaki M; Iwade K; Kimata S; Hosoda S
    Nihon Rinsho; 1992 Feb; 50(2):397-402. PubMed ID: 1613997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries.
    Motovska Z; Kala P
    Clin Ther; 2008; 30 Pt 2():2191-202. PubMed ID: 19281914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel.
    Prescrire Int; 2009 Oct; 18(103):193-5. PubMed ID: 19877380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.